Abstract
Two forms of regional chemotherapy for the treatment of advanced melanoma or sarcoma of the extremity are isolated limb perfusion (ILP) and the more recently described isolated limb infusion (ILI). Melphalan is the most commonly employed agent in both ILP and ILI, although it is often used in conjunction with other cytotoxic and/or biologic therapies. While ILP and ILI are far more effective for the treatment of extremity disease than is systemic therapy, there is still significant room for improvement in outcomes, from the standpoint of both response rate and toxicity. An understanding of the pharmacokinetics of regional chemotherapy would allow for the prediction of tumor response and toxicity and therefore patient outcomes. In addition, elucidating the mechanisms of drug resistance would lead to opportunities to develop effective chemo-modulators that enhance the effectiveness of ILP and ILI. This paper reviews progress in these two key areas of active investigation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 239-249 |
| Number of pages | 11 |
| Journal | International Journal of Hyperthermia |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemo-modulator
- Glutathione
- Isolated limb infusion
- Isolated limb perfusion
- Two-compartment model
ASJC Scopus subject areas
- Cancer Research
- Radiological and Ultrasound Technology
Cite this
Pharmacokinetics and drug resistance of melphalan in regional chemotherapy : ILP versus ILI. / Padussis, James C.; Steerman, Samuel N.; Tyler, Douglas; Mosca, Paul J.
In: International Journal of Hyperthermia, Vol. 24, No. 3, 05.2008, p. 239-249.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetics and drug resistance of melphalan in regional chemotherapy
T2 - ILP versus ILI
AU - Padussis, James C.
AU - Steerman, Samuel N.
AU - Tyler, Douglas
AU - Mosca, Paul J.
PY - 2008/5
Y1 - 2008/5
N2 - Two forms of regional chemotherapy for the treatment of advanced melanoma or sarcoma of the extremity are isolated limb perfusion (ILP) and the more recently described isolated limb infusion (ILI). Melphalan is the most commonly employed agent in both ILP and ILI, although it is often used in conjunction with other cytotoxic and/or biologic therapies. While ILP and ILI are far more effective for the treatment of extremity disease than is systemic therapy, there is still significant room for improvement in outcomes, from the standpoint of both response rate and toxicity. An understanding of the pharmacokinetics of regional chemotherapy would allow for the prediction of tumor response and toxicity and therefore patient outcomes. In addition, elucidating the mechanisms of drug resistance would lead to opportunities to develop effective chemo-modulators that enhance the effectiveness of ILP and ILI. This paper reviews progress in these two key areas of active investigation.
AB - Two forms of regional chemotherapy for the treatment of advanced melanoma or sarcoma of the extremity are isolated limb perfusion (ILP) and the more recently described isolated limb infusion (ILI). Melphalan is the most commonly employed agent in both ILP and ILI, although it is often used in conjunction with other cytotoxic and/or biologic therapies. While ILP and ILI are far more effective for the treatment of extremity disease than is systemic therapy, there is still significant room for improvement in outcomes, from the standpoint of both response rate and toxicity. An understanding of the pharmacokinetics of regional chemotherapy would allow for the prediction of tumor response and toxicity and therefore patient outcomes. In addition, elucidating the mechanisms of drug resistance would lead to opportunities to develop effective chemo-modulators that enhance the effectiveness of ILP and ILI. This paper reviews progress in these two key areas of active investigation.
KW - Chemo-modulator
KW - Glutathione
KW - Isolated limb infusion
KW - Isolated limb perfusion
KW - Two-compartment model
UR - http://www.scopus.com/inward/record.url?scp=42049119491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42049119491&partnerID=8YFLogxK
U2 - 10.1080/02656730701816410
DO - 10.1080/02656730701816410
M3 - Article
VL - 24
SP - 239
EP - 249
JO - International Journal of Hyperthermia
JF - International Journal of Hyperthermia
SN - 0265-6736
IS - 3
ER -